CATUG operates an integrated R&D, analytical, and GMP manufacturing network designed to support complex therapeutic programs from process development to GMP-oriented CMC execution. With more than 10,000 m² of GMP workshop space, the network supports plasmid DNA, RNA drug substance, LNP drug product, sterile vial filling, and pre-filled syringe filling activities.

Across its Suzhou and Wuhan sites, CATUG has established 4 plasmid production lines, 2 RNA drug substance production lines, 3 LNP production lines, 2 sterile vial filling lines, and 1 pre-filled syringe filling line. The facilities are supported by quality control laboratories and a central R&D laboratory of more than 2,000 m², and are designed and operated in alignment with FDA, EMA, and NMPA GMP expectations.